Displaying all 5 publications

Abstract:
Sort:
  1. Hishar, H., Salasiah, M., Fathinul Fikri, A. S., Nordin, A. J.
    MyJurnal
    A shift to administration of optimal dose of 18F-FDG between 4 and 5 MBq/kg from the current practice of higher doses potentially yields a reasonable-to-excellent PET image. For this purpose, whole-body MIP images of 32 patients (23 men, 9 women, age 51.9 ± 13.7 years), administered with 18F-FDG (activity 5.3 ± 0.5 MBq/kg, 45 minutes uptake time) for whole-body PET/CT examinations, were evaluated. Image quality was assessed visually by two radiologists using a three-point scoring scale: poor, reasonable and excellent. The interobserver agreement revealed a kappa value higher than 0.7. Therefore, the utilisation of 18F-FDG dose between 4 and 5MBq/kg is considered an optimum dose for whole-body PET/CT examination.
  2. Fathinul F, Nordin AJ, Lau WF
    Cell Biochem Biophys, 2013 May;66(1):37-43.
    PMID: 22790883 DOI: 10.1007/s12013-012-9395-5
    Molecular imaging employing (18)[F]FDG-PET/CT enables in-vivo visualization, characterisation and measurement of biological process in tumour at the molecular and cellular level. In oncology, this approach can be directly applied as translational biomarkers of disease progression. In this article, the improved roles of FDG as an in-vivo glycolytic marker which reflect biological changes across in-vitro cellular environment are discussed. New understanding in how altered metabolism via glycolytic downstream drivers of malignant transformation as reviewed below offers unique promise as to monitor tumour aggressiveness and hence optimize the therapeutic management.
  3. Suppiah S, Ching SM, Nordin AJ, Vinjamuri S
    Med J Malaysia, 2018 06;73(3):141-146.
    PMID: 29962497
    BACKGROUND: Imaging such as Tc99m-HMPAO single photon emission computed tomography (SPECT), and positron emission tomography/ computed tomography (PET/CT) amyloid scans are used to aid the diagnosis of Alzheimer's disease (AD).

    OBJECTIVE: We aimed to correlate the ability of these modalities to differentiate Probable AD and Possible AD using the clinical diagnosis as a gold standard. We also investigated the correlation of severity of amyloid deposit in the brain with the diagnosis of AD.

    METHODS: A retrospective study of 47 subjects (17 Probable AD and 30 Possible AD) who were referred for PET/CT amyloid scans to our centre was conducted. Hypoperfusion in the temporo-parietal lobes on Tc99m-HMPAO SPECT and loss of grey-white matter contrast in cortical regions on PET/CT Amyloid scans indicating the presence of amyloid β deposit were qualitatively interpreted as positive for AD. SPECT and PET/CT were also read in combination (Combo reading). The severity of amyloid β deposit was semiquantitatively assessed in a visual binary method using a scale of Grade 0-4. The severity of amyloid β deposit was assessed in a visual binary method and a semi-quantitative method using a scale of Grade 0-4.

    RESULTS: There was significant correlation of Tc99m-HMPAO SPECT, PET/CT amyloid findings and Combo reading with AD. The sensitivity, specificity, PPV and NPV were 87.5%, 73.7%, 58.3% and 93.3% (SPECT); 62.5%, 77.4%, 58.8% and 80.0% (PET/CT) and 87.5%, 84.2%, 70.0% and 30.0% (Combo reading) respectively. The grade of amyloid deposition was not significantly correlated with AD (Spearman's correlation, p=0.687).

    CONCLUSION: There is an incremental benefit in utilizing PET/CT amyloid imaging in cases with atypical presentation and indeterminate findings on conventional imaging of Alzheimer's disease.

  4. Fathinul Fikri AS, Dharmendran R, Vikneswaran P, Nordin AJ
    Abdom Imaging, 2015 Aug;40(6):1457-64.
    PMID: 25576048 DOI: 10.1007/s00261-014-0343-2
    A study was undertaken to investigate the value of pretreatment PET-CT in predicting survival in patients with oesophageal cancer (OC).
  5. Fikri AS, Kroiss A, Ahmad AZ, Zanariah H, Lau WF, Uprimny C, et al.
    Acta Radiol, 2014 Jun;55(5):631-40.
    PMID: 24037430 DOI: 10.1177/0284185113504330
    To our knowledge, data are lacking on the role of 18F-FDG PET/CT in the localization and prediction of neuroendocrine tumors, in particular the pheochromocytoma/paraganglioma (PCC/PGL) group.
Filters
Contact Us

Please provide feedback to Administrator ([email protected])

External Links